INVA Valuation

Innoviva Inc

Add to Watchlist

Advanced Chart

19.890

+0.51(2.632%)1D

Overview
Forecast
Valuation
Earnings

INVA Relative Valuation

INVA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, INVA is overvalued; if below, it's undervalued.

Historical Valuation

Innoviva Inc (INVA) is now in the Fair zone, suggesting that its current forward PE ratio of 9.67 is considered Fairly compared with the five-year average of 11.61. The fair price of Innoviva Inc (INVA) is between 13.00 to 33.14 according to relative valuation methord.

Relative Value

Fair Zone

13.00-33.14

Current Price：19.57

Fair

9.67

Trailing

Forward

0.00

EV/EBITDA

Innoviva Inc. (INVA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 7.12. The thresholds are as follows: Strongly Undervalued below 1.68, Undervalued between 1.68 and 4.40, Fairly Valued between 9.84 and 4.40, Overvalued between 9.84 and 12.56, and Strongly Overvalued above 12.56. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

7.02

EV/EBIT

Innoviva Inc. (INVA) has a current EV/EBIT of 7.02. The 5-year average EV/EBIT is 8.52. The thresholds are as follows: Strongly Undervalued below 2.86, Undervalued between 2.86 and 5.69, Fairly Valued between 11.35 and 5.69, Overvalued between 11.35 and 14.18, and Strongly Overvalued above 14.18. The current Forward EV/EBIT of 7.02 falls within the Historic Trend Line -Fairly Valued range.

3.08

Innoviva Inc. (INVA) has a current PS of 3.08. The 5-year average PS is 3.51. The thresholds are as follows: Strongly Undervalued below 1.95, Undervalued between 1.95 and 2.73, Fairly Valued between 4.29 and 2.73, Overvalued between 4.29 and 5.06, and Strongly Overvalued above 5.06. The current Forward PS of 3.08 falls within the Historic Trend Line -Fairly Valued range.

5.67

P/OCF

Innoviva Inc. (INVA) has a current P/OCF of 5.67. The 5-year average P/OCF is 4.10. The thresholds are as follows: Strongly Undervalued below -6.26, Undervalued between -6.26 and -1.08, Fairly Valued between 9.27 and -1.08, Overvalued between 9.27 and 14.45, and Strongly Overvalued above 14.45. The current Forward P/OCF of 5.67 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Innoviva Inc. (INVA) has a current P/FCF of 0.00. The 5-year average P/FCF is 1.29. The thresholds are as follows: Strongly Undervalued below -4.24, Undervalued between -4.24 and -1.47, Fairly Valued between 4.06 and -1.47, Overvalued between 4.06 and 6.83, and Strongly Overvalued above 6.83. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Innoviva Inc (INVA) has a current Price-to-Book (P/B) ratio of 1.71. Compared to its 3-year average P/B ratio of 1.57 , the current P/B ratio is approximately 8.52% higher. Relative to its 5-year average P/B ratio of 2.00, the current P/B ratio is about -14.62% higher. Innoviva Inc (INVA) has a Forward Free Cash Flow (FCF) yield of approximately 16.44%. Compared to its 3-year average FCF yield of 17.04%, the current FCF yield is approximately -3.51% lower. Relative to its 5-year average FCF yield of 22.05% , the current FCF yield is about -25.45% lower.

1.71

P/B

Median3y

1.57

Median5y

2.00

16.40

FCF Yield

Median3y

17.04

Median5y

22.05

Competitors Valuation Multiple

The average P/S ratio for INVA's competitors is 7.38, providing a benchmark for relative valuation. Innoviva Inc Corp (INVA) exhibits a P/S ratio of 3.08, which is -58.29% above the industry average. Given its robust revenue growth of 0.39%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Pacira Biosciences Inc

Structure Therapeutics Inc

24.94

1.34B

AMLX.O

Amylyx Pharmaceuticals Inc

Performance Decomposition

Market capitalization of INVA increased by 0.36% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 9.50 to 36.36.

The secondary factor is the Revenue Growth, contributed 0.39%to the performance.

Overall, the performance of INVA in the past 1 year is driven by P/E Change. Which is more unsustainable.

0.39%

99.90M → 100.28M

Revenue Growth

-282.92%

-34.72 → 63.51

Margin Expansion

282.89%

9.50 → 36.36

P/E Change

0.36%